NICE now proposes to recommend Stelara for psoriatic arthritis

9 December 2014

In a U-turn for UK health cost watchdog, the National Institute for Health and Care Excellence (NICE) has opened a consultation on its draft guidance which proposes recommending US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Stelara (ustekinumab) as a treatment option for psoriatic arthritis in certain circumstances.

Earlier this year, NICE issued technology appraisal guidance 313 which did not recommend using ustekinumab alone or in combination with methotrexate, for treating active psoriatic arthritis in adults when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate.

This new draft guidance – which now proposes recommending ustekinumab in specific circumstances – is a rapid review of TA313 following the introduction of a patient access scheme which the company that manufactures ustekinumab has agreed with the Department of Health.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK